Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven®

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 3, 2000, Pages 239-242

  Johannessen, M ^a   Andreasen, R B ^a   Nordfang, O ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Hemophilia; Inhibitors; Recombinant activated FVII

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

FACTOR IX; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0034036716     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. 1. Aledort L. Inhibitors in hemophilia patients - current status and management. Am J Hematol 1994; 47: 208-217.
2. 2. Laurian Y, Girma JP, Lambert T, Meyer D, Larrieu MJ. Incidence of immune responses following 102 infusions of Autoplex in 18 hemophilic patients with antibody to factor VIII. Blood 1984; 63: 457-462.
3. 3. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coag Fibrinol 1998; 9: 119-128.
4. 4. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
5. 5. Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coag Fibrinol 1998; 9: S93-S95.
6. 6. Shapiro AD. American experience with home-use of NovoSeven - recombinant factor VIIa in hemophiliacs with inhibitors. Haemostasis 1996; 26: 143-149.
7. 7. Verbrüggen B, Novakova I, Wessels H, Boezman J, Van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for FVIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
8. 8. Black FL, Rosen L. Patterns of measels antibodies in residents of Tahiti and their stability in the absence of exposure. J Immunol 1966; 88: 725-731.
9. 9. Coonet EL, Collier AC, Greenberg PD. Safety and immunological response to a recombinant virus vaccine expressing HIV-1 glycoprotein. Lancet 1991; 337: 567-572.
10. 10. Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 200-204.